This study assesses virologic response, safety, tolerability, and changes in health-related quality of life (HRQoL) in antiretroviral (ARV)-naive patients treated with 2 atazanavir (ATV)-based regimens over 96 weeks. Treatment-naive adult patients (n = 200) were randomized to receive either ATV 300 mg with ritonavir (RTV) 100 mg (ATV300/r, n = 95) or ATV 400 mg (ATV400; n = 105). At week 96, 75% of ATV300/r-treated and 70% of ATV400-treated patients achieved viral loads <400 copies/mL (difference estimate [95% confidence interval, CI] = 5.1 [-7.1 to 17.2]). Five and 20 patients, respectively, experienced virologic failure. Adverse event-related discontinuations occurred among 8% receiving ATV300/r and 3% receiving ATV400. Plasma lipid elevations were generally low. Both regimens were well tolerated and associated with sustained improvements in HRQoL. These findings demonstrate long-term efficacy, tolerability, and safety of both ATV300/r and ATV400 in ARV-naive patients through 96 weeks with improvements in HRQoL.
Dhhs.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, 1-139. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf . Accessed November 3, 2008.
2.
Hammer SM, Eron JJ Jr, Reiss P., et al., for the International AIDS Society-USA.Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300(5):555-570.
3.
Molina JM, Andrade-Villanueva J., Echevarria J., et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008; 372(9639):646-655.
4.
Molina JM, Andrade-Villanueva J., Echevarria J., et al. Atazananavir/ritonivir vs lopinavir/ritonavir in antiretroviral-naïve HIV-1-infected patients: CASTLE 96 week efficacy and safety. Poster presented at: the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Disease Society of America Conference ; 2008;Washington, DC; abstract H-1250d.
5.
Johnson M., Grinsztejn B., Rodriguez C., et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ ritonavir in patients with multiple virologic failures. AIDS. 2006;20(5):711-718.
6.
Flexner C.Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. Annu Rev Pharmacol Toxicol. 2000;40:649-674.
7.
Tomaka F., Lefebvre E., Sekar V., et al. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers . HIV Medicine, published online February 5, 2009. DOI 10.1111/j.1468-1293. 2008.00690.x.
8.
Noor MA, Parker RA, O’Mara E., et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS. 2004; 18(16):2137-2144.
9.
Noor MA, Flint OP, Maa JF, Parker RAEffects of atazanavir/ ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically . AIDS. 2006;20(14):1813-1821.
10.
Gatell J., Salmon-Ceron D., Lazzarin A., et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis. 2007; 44(11):1484-1492.
11.
Keiser P., McGrath S., Reynolds L., et al. Changes in lipid profiles in treatment-experienced patients switched to atazanavir-based antiretroviral therapy: results from the Atazanavir Early Access Program (EAP). Poster presented at: XVI International AIDS Conference; 2006; Toronto, Canada; abstract WePe0163.
12.
Sension M., Grinsztejn B., Molina J., et al. Improvement in lipid profiles after 12 weeks of switching to atazanavir from boosted or unboosted protease inhibitors in patients with no previous PI virologic failure and hyperlipidemia at baseline. Poster presented at: 12th Conference on Retroviruses and Opportunistic Infections; 2005; Boston, MA; abstract 858.
13.
Reyataz [package insert]. Princeton, NJ: Bristol-Myers Squibb Company. Available from URL: http://packageinserts.bms.com/pi/pi_reyataz.pdf (2009).
14.
Delfraissy JF, Moreno S., Sanz-Moreno J., Carosi G., Pokrovsky V., Lazzarin A.Efficacy and safety of 48 weeks maintenance with once-daily ATV and ATV/r in patients with viral load < 50 c/ mL after induction with ATV/r. Poster presented at: 9th International Congress on Drug Therapy in HIV Infection; 2008; Glasgow, UK; abstract O415.
15.
A multicenter, randomized, open-label, active-controlled pilot study to evaluate the safety and antiretroviral activity of unboosted atazanavir BID plus raltegravir BID and boosted atazanavir QD in combination with tenofovir/emtricitabine QD in treatment naïve HIV-infected subjects. http://clinicaltrials.gov [identifier NCT00768989]. Accessed December 8, 2008.
16.
Malan DR, Krantz E., David N., Wirtz V., Hammond J., McGrath D.Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naïve patients. J Acquir Immune Defic Syndr. 2008 ;47(2):161-167.
17.
Casado A., Consiglio E., Podzamczer D., Badia X.Highly active antiretroviral treatment (HAART) and health-related quality of life in naïve and pretreated HIV-infected patients. HIV Clin Trials. 2001;2(6):477-483.
18.
Nieuwkerk PT , Gisolf EH, Reijers MH, Lange JM, Danner SA, Sprangers MALong-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection. AIDS. 2001;15(15):1985-1991.
19.
Wu AW, Revicki DA, Jacobson D., Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res . 1997; 6(6):481-493.
20.
Johnson VA, Brun-Vézinet F., Clotet B., et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med.2007;15(4):119-125.
21.
Bartlett JA , Johnson J., Herrera G., et al. Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir, or stavudine. J Acquir Immune Defic Syndr. 2006;43(3):284-292.
22.
Mills A., Nelson M., Jayaweera D., et al. ARTEMIS: efficacy and safety of darunavir/ritonavir (DRV/r) 800/100 mg once-daily vs lopinavir/ritonavir (LPV/r) in treatment-naive, HIV-1-infected patients at 96 wks. In: Program and abstracts of the 48th Annual ICAAC/IDSA 46th Annual Meeting; October 25-28, 2008; Washington, DC; abstract H-1250c.
23.
Conradie F. , Sanne I., Venter W., Eron J.Failure of lopinavirritonavir (Kaletra)-containing regimen in an antiretroviral-naïve patient. AIDS. 2004;18(7):1084-1085.
24.
Friend J., Parkin N., Liegler T., Martin JN, Deeks SGIsolated lopinavir resistance after virological rebound of a ritonavir/ lopinavir-based regimen. AIDS. 2004;18(14):1965-1966.
25.
Sax PE, Xu F., Tisdale M., Elston R.First report of development of resistance to boosted fosamprenavir in an art-naïve subject: virologic and clinical outcome. Poster presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy ; 2005; Washington DC; abstract H-1060.
26.
Murphy RL, Sanne I., Cahn P., et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naïve subjects: 48-week results . AIDS. 2003;17(18): 2603-2614.
27.
Squires K., Lazzarin A., Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr . 2004;36(5):1011-1019.
28.
Friis-Moller N., Sabin CA, Weber R., et al., and the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group.Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993-2003.
29.
Klein D., Hurley L., Quesenberry C., Silverberg M., Horberg M., Sidney S.Hospitalizations for CHD and MI among Northern California HIV+ and HIV- men: changes in practice and Framingham risk scores. Poster presented at: 13th Conference on Retroviruses and Opportunistic Infections ; 2006; Denver, CO; abstract 737.
30.
Mary-Krause M., Cotte L., Simon A., Partisani M., Costagliola D.Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003; 17(17):2479-2486.
31.
Gallant JE, Staszewski S., Pozniak AL, et al., and the 903 Study Group.Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. JAMA. 2004;292(2):191-201.
32.
Podzamczer D., Ferrer E., Sanchez P., et al., and the ABCDE (Abacavir vs. d4T (stavudine) plus efavirenz) Study Team.Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr.2007;44(2):139-147.
33.
Liu C., Weber K., Robison E. et al. Assessing the effect of HARRT on change in quality of life among HIV-infected women. AIDS Research and Therapy. 2006;3:6.
34.
Conway B.The role of adherence to antiretroviral therapy in the management of HIV infection . J Acquir Immune Defic Syndr. 2007;45(suppl 1):S14-S18.
35.
Mills AM, Nelson M., Jayaweera D., et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naïve, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23(13): 1679-1688.
36.
Sanne I., Piliero P., Squires K., Thiry A., Schnittman S.Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naïve subjects. J Acquir Immune Defic Syndr. 2003;32(1):18-29.
37.
Eron J., Yeni P., Gathe J., et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomized non-inferiority trial. Lancet. 2006;368(9534):476-482.
